Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)

JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)

基本信息

  • 批准号:
    8286969
  • 负责人:
  • 金额:
    $ 61.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-08-14 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Statin therapy for cardiovascular disease prevention is a mainstay of treatment. However, emerging data suggest that statin initiation is also accompanied by a modest increase in risk of clinical diabetes. Six large randomized clinical trials have collected data on diabetes outcomes and demonstrate a modest but highly significant effect (summary relative risk: 1.13; 95% CI 1.03-1.24, p=0.007) that does not appear to be drug or dose specific, nor easily predicted on the basis of traditional risk factors. The mechanisms of statin-induced diabetes are currently unknown, but the pleiotropic effects of these agents suggest multiple pathways should be considered. The JUPITER trial in which 17,802 apparently healthy non-diabetic men and women were initiated on rosuvastatin (20 mg per day) or placebo offers a unique opportunity in which to examine this issue. The relative risk of diabetes associated with random allocation to rosuvastatin in JUPITER was 1.26 (1.05-1.51; p=0.02). Employing two complementary prospective approaches, we propose to comprehensively evaluate a series of biomarkers reflecting twelve plausible mechanisms of statin-induced diabetes. These will include biomarkers of: 1) insulin resistance, 2) 2-cell function, 3) adipocyte signaling, 4) hepatic dysfunction/iron overload, 5) lipid metabolism, 6) growth factor activity, 7) apoptosis, 8) inflammation, 9) endothelial dysfunction, 10) branched chain amino acid metabolism, 11) natriuretic peptide activity and 12) osteo-endocrine regulation. In Phase One of this research program, we will evaluate statin effects on these pathways by measuring change in biomarker levels from baseline to 1-year in a representative sample of JUPITER participants (400 allocated to rosuvastatin and 400 allocated to placebo). In Phase Two, utilizing a prospective case-cohort approach, we will also assess biomarker relationships with clinical type 2 diabetes. Case subjects (n=540) will be JUPITER participants who were free of clinical or biochemical (fasting plasma glucose < 126 mg/dL) diabetes at baseline who develop clinical or biochemical (fasting plasma glucose > 126 mg/dL) diabetes during follow-up. The subcohort (n=2,000) will be a randomly selected sample of the parent JUPITER population. Biomarkers will be assessed in pathophysiologic groups based upon plausible biologic pathways as well as data generated in Phase One. Data on usual demographic, clinical and behavioral risk factors will be used to evaluate potential confounding and effect modification. These analyses will take advantage of a unique blood bank from a cohort of 17,802 primary prevention patients that is ethnically diverse (>5000 non-Caucasian participants) and includes 6,801 women and will thus provide a cost-efficient method to evaluate statin therapy and diabetes risk in an unprecedented manner. If funded, the findings generated from this application should additionally provide a method for identifying those at greatest risk of type 2 diabetes, an issue that is likely to increase in importance as indications for statin therapy continue to broaden. PUBLIC HEALTH RELEVANCE: The cardiovascular benefit of HMG-CoA reductace inhibitors (statins) is unequivocal. However, recently published data deriving from several large randomized clinical trials of statin initiation for cardiovascular disease prevention have raised concern regarding a modest increase in risk of type 2 diabetes. This effect does not appear to be drug or dose specific, nor easily predicted on the basis of traditional risk factors. Findings from this prospective evaluation of statin-induced diabetes within the Justification for the Use of Statins in Prevention: and Intervention trial Evaluating Rosuvastatin (JUPITER) trial will clarify the impact of statins on multiple metabolic pathways implicated in diabetogenesis and will offer a method of identifying individuals at greatest risk for drug-associated diabetes, an issue likely to take on increasing importance as indications for statin therapy expand.
描述(由申请人提供):用于预防心血管疾病的他汀类药物治疗是治疗的主要手段。但是,新兴的数据表明他汀类药物的启动还伴随着临床糖尿病风险的适度增加。六项大型随机临床试验已经收集了有关糖尿病预后的数据,并证明了适度但非常重要的影响(摘要相对风险:1.13; 95%CI 1.03-1.24,p = 0.007)似乎不是药物或剂量特异性,也不容易根据传统风险因素进行预测。他汀类药物诱导的糖尿病的机制目前尚不清楚,但是这些药物的多效作用表明应该考虑多种途径。木星试验在rosuvastatin(每天20毫克)或安慰剂中发起了17,802名显然健康的非糖尿病男性和女性,提供了一个独特的机会来检查这个问题。与木星中随机分配与余地蛋白蛋白的随机分配相关的糖尿病的相对风险为1.26(1.05-1.51; p = 0.02)。我们采用两种互补的前瞻性方法,建议全面评估一系列反映他汀类药物诱导的糖尿病的合理机制的生物标志物。这些将包括:1)生物标志物:1)胰岛素抵抗,2)2细胞功能,3)脂肪细胞信号传导,4)肝功能障碍/铁超负荷,5)5)脂质代谢,6)生长因子活性,7)凋亡,8)炎症,8)炎症,9)9)12)内皮动作障碍,10)分支机构抗蛋白抗蛋白酸性蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白含有蛋白质蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白蛋白含量是弥补的,纽扣骨内分泌调节。在该研究计划的第一阶段,我们将通过在木星参与者的代表性样本中测量从基线到1年的生物标志物水平的变化来评估他汀类药物对这些途径的影响(分配给Rosuvastatin的400个和分配给安慰剂的400个)。在第二阶段,利用前瞻性病例 - 霍特方法,我们还将评估与临床2型糖尿病的生物标志物关系。病例受试者(n = 540)将是基线的木星参与者,他们没有临床或生化(禁食等离子体葡萄糖<126 mg/dl)糖尿病,他们在随访期间患有临床或生化(禁食等离子体葡萄糖> 126 mg/dl)糖尿病。子体位(n = 2,000)将是父木星种群的随机选择样本。将根据合理的生物学途径以及在第一阶段产生的数据中评估生物标志物在病理生理组中进行评估。关于常规人口,临床和行为风险因素的数据将用于评估潜在的混杂和影响修改。这些分析将利用17,802名初级预防患者队列的独特血库,这些患者在种族上多样化(> 5000名非可口可乐参与者),其中包括6,801名女性,因此将提供一种以固定方式评估他汀类药物治疗和糖尿病风险的成本效益方法。如果获得资助,则从本申请中产生的发现还应提供一种识别最大风险2型糖尿病风险的方法,这一问题可能会增加重要性,因为他汀类药物治疗的指示继续扩大。 公共卫生相关性:HMG-COA还原抑制剂(他汀类药物)的心血管益处是明确的。但是,最近发布的数据来自几项针对预防心血管疾病的他汀类药物启动的大型随机临床试验,这引起了人们对2型糖尿病风险的适度增加的关注。这种作用似乎不是药物或剂量特定的,也不是根据传统危险因素进行预测的。从这种对他汀类药物使用毒素的理由中对他汀类毒素诱发的糖尿病的预期评估的结果以及评估rosuvastatin(jupiter)试验的干预试验将阐明他汀类药物对糖尿病发生涉及多种代谢途径的影响,并将为识别药物症状的依赖的型号的识别,并可能会增加持续性的持续性,并可能会增加持续性的静态疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Aruna Das Pradhan其他文献

HYPERTRIGLYCERIDEMIA, INFLAMMATION, HYPERCHOLESTEROLEMIA, AND FUTURE CARDIOMETABOLIC DISEASE RISK: A DATA DRIVEN CLUSTER ANALYSIS IN THE WOMEN's HEALTH STUDY
  • DOI:
    10.1016/s0735-1097(20)32490-6
    10.1016/s0735-1097(20)32490-6
  • 发表时间:
    2020-03-24
    2020-03-24
  • 期刊:
  • 影响因子:
  • 作者:
    Edward Duran;Nancy R. Cook;Aaron W. Aday;Julie E. Buring;Paul M. Ridker;Aruna Das Pradhan
    Edward Duran;Nancy R. Cook;Aaron W. Aday;Julie E. Buring;Paul M. Ridker;Aruna Das Pradhan
  • 通讯作者:
    Aruna Das Pradhan
    Aruna Das Pradhan
Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT
  • DOI:
    10.1016/j.jacc.2024.05.028
    10.1016/j.jacc.2024.05.028
  • 发表时间:
    2024-07-23
    2024-07-23
  • 期刊:
  • 影响因子:
  • 作者:
    Lucas L. Marinho;Brendan M. Everett;Aaron W. Aday;Frank L.J. Visseren;Jean G. MacFadyen;Elaine Zaharris;Jorge Plutzky;Raul D. Santos;Peter Libby;Jean-Charles Fruchart;Paul M Ridker;Aruna Das Pradhan
    Lucas L. Marinho;Brendan M. Everett;Aaron W. Aday;Frank L.J. Visseren;Jean G. MacFadyen;Elaine Zaharris;Jorge Plutzky;Raul D. Santos;Peter Libby;Jean-Charles Fruchart;Paul M Ridker;Aruna Das Pradhan
  • 通讯作者:
    Aruna Das Pradhan
    Aruna Das Pradhan
TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES, RACE/ETHNIC GROUP AND FUTURE CARDIOVASCULAR EVENTS:THE MESA STUDY
  • DOI:
    10.1016/s0735-1097(22)02544-x
    10.1016/s0735-1097(22)02544-x
  • 发表时间:
    2022-03-08
    2022-03-08
  • 期刊:
  • 影响因子:
  • 作者:
    Edward Duran;David R. Jacobs;Aruna Das Pradhan;Aaron W. Aday;Daniel A. Duprez
    Edward Duran;David R. Jacobs;Aruna Das Pradhan;Aaron W. Aday;Daniel A. Duprez
  • 通讯作者:
    Daniel A. Duprez
    Daniel A. Duprez
共 3 条
  • 1
前往

Aruna Das Pradhan的其他基金

Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD
小剂量甲氨蝶呤抗炎治疗可减少 PAD
  • 批准号:
    9272427
    9272427
  • 财政年份:
    2014
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD
小剂量甲氨蝶呤抗炎治疗可减少 PAD
  • 批准号:
    8738800
    8738800
  • 财政年份:
    2014
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD
小剂量甲氨蝶呤抗炎治疗可减少 PAD
  • 批准号:
    8913257
    8913257
  • 财政年份:
    2014
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Diabetes Prevention in the Vitamin D and Omega-3 Trial
维生素 D 和 Omega-3 试验中的糖尿病预防
  • 批准号:
    8516502
    8516502
  • 财政年份:
    2010
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)
JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)
  • 批准号:
    7946012
    7946012
  • 财政年份:
    2010
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Diabetes Prevention in the Vitamin D and Omega-3 Trial
维生素 D 和 Omega-3 试验中的糖尿病预防
  • 批准号:
    8689001
    8689001
  • 财政年份:
    2010
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)
JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)
  • 批准号:
    8507268
    8507268
  • 财政年份:
    2010
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)
JUPITER 中他汀类药物诱发 DM 的机制(用于预防 CVD 的瑞舒伐他汀)
  • 批准号:
    8123463
    8123463
  • 财政年份:
    2010
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Novel and Traditional Risk Factors for Symptomatic PAD in Women
女性症状性 PAD 的新的和传统的危险因素
  • 批准号:
    7762747
    7762747
  • 财政年份:
    2006
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Novel and Traditional Risk Factors for Symptomatic PAD in Women
女性症状性 PAD 的新的和传统的危险因素
  • 批准号:
    7384412
    7384412
  • 财政年份:
    2006
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:

相似国自然基金

签字注册会计师动态配置问题研究:基于临阵换师视角
  • 批准号:
    72362023
  • 批准年份:
    2023
  • 资助金额:
    28 万元
  • 项目类别:
    地区科学基金项目
全生命周期视域的会计师事务所分所一体化治理与审计风险控制研究
  • 批准号:
    72372064
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
会计师事务所数字化能力构建:动机、经济后果及作用机制
  • 批准号:
    72372028
  • 批准年份:
    2023
  • 资助金额:
    42.00 万元
  • 项目类别:
    面上项目
会计师事务所薪酬激励机制:理论框架、激励效应检验与优化重构
  • 批准号:
    72362001
  • 批准年份:
    2023
  • 资助金额:
    28.00 万元
  • 项目类别:
    地区科学基金项目
环境治理目标下的公司财务、会计和审计行为研究
  • 批准号:
    72332002
  • 批准年份:
    2023
  • 资助金额:
    165.00 万元
  • 项目类别:
    重点项目

相似海外基金

The GROWTH Study, Glycemia Range and Offspring Weight and adiposity in response To Human milk
生长研究、血糖范围以及后代体重和肥胖对母乳的反应
  • 批准号:
    10595445
    10595445
  • 财政年份:
    2023
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Adiponectin on cerebrovascular regulation in vascular cognitive impairment and dementia (VCID)
脂联素对血管性认知障碍和痴呆 (VCID) 的脑血管调节作用
  • 批准号:
    10542359
    10542359
  • 财政年份:
    2022
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Adiponectin on cerebrovascular regulation in vascular cognitive impairment and dementia (VCID)
脂联素对血管性认知障碍和痴呆 (VCID) 的脑血管调节作用
  • 批准号:
    10338744
    10338744
  • 财政年份:
    2022
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Adipokines, Sex Hormones and Cardiac Dysfunction in Postmenopausal Women of the MESA Study – An analysis of Secondary Data
MESA 研究中绝经后妇女的脂肪因子、性激素和心脏功能障碍 — 二手数据分析
  • 批准号:
    10507719
    10507719
  • 财政年份:
    2022
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别:
Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition
通过 APJ 抑制靶向卵巢癌球体形成和代谢适应
  • 批准号:
    10366717
    10366717
  • 财政年份:
    2021
  • 资助金额:
    $ 61.19万
    $ 61.19万
  • 项目类别: